BR112013009086A2 - tratamento de câncer/inibição de metástase - Google Patents
tratamento de câncer/inibição de metástaseInfo
- Publication number
- BR112013009086A2 BR112013009086A2 BR112013009086A BR112013009086A BR112013009086A2 BR 112013009086 A2 BR112013009086 A2 BR 112013009086A2 BR 112013009086 A BR112013009086 A BR 112013009086A BR 112013009086 A BR112013009086 A BR 112013009086A BR 112013009086 A2 BR112013009086 A2 BR 112013009086A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer treatment
- inhibition
- reducing
- metastasis inhibition
- metastasis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 title abstract 3
- 206010027476 Metastases Diseases 0.000 title abstract 2
- 230000009401 metastasis Effects 0.000 title abstract 2
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 abstract 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000008883 metastatic behaviour Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 229960000213 ranolazine Drugs 0.000 abstract 1
- 229960004181 riluzole Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2010/001908 WO2012049440A1 (en) | 2010-10-13 | 2010-10-13 | Treatment of cancer/inhibition of metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013009086A2 true BR112013009086A2 (pt) | 2016-07-26 |
Family
ID=44022817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013009086A BR112013009086A2 (pt) | 2010-10-13 | 2010-10-13 | tratamento de câncer/inibição de metástase |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20130203764A1 (https=) |
| EP (4) | EP2627321A1 (https=) |
| JP (1) | JP2013539778A (https=) |
| KR (1) | KR20140032346A (https=) |
| CN (2) | CN112755029A (https=) |
| AU (2) | AU2010362412A1 (https=) |
| BR (1) | BR112013009086A2 (https=) |
| CA (1) | CA2851694C (https=) |
| DK (1) | DK3132791T3 (https=) |
| IL (1) | IL225689A0 (https=) |
| RU (1) | RU2013121744A (https=) |
| SG (1) | SG189352A1 (https=) |
| WO (1) | WO2012049440A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013009086A2 (pt) | 2010-10-13 | 2016-07-26 | Mustafa Bilgin Ali Djamgoz | tratamento de câncer/inibição de metástase |
| WO2013123403A1 (en) * | 2012-02-15 | 2013-08-22 | Sanford-Burnham Medical Research Institute | Theranostics platform and methods of use |
| WO2017091574A1 (en) * | 2015-11-25 | 2017-06-01 | Health Research, Inc. | Riluzole and riluzole drug combinations for the treatment of prostate cancer |
| JP6465306B2 (ja) * | 2016-02-04 | 2019-02-06 | セレックス・オンコロジー・リミテッド | 癌の治療／転移の阻害 |
| LT3458053T (lt) * | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
| AU2018218341B2 (en) * | 2017-02-10 | 2023-07-06 | Celex Oncology Innovations Limited | Treatment of cancer and inhibition of metastasis |
| US20200123544A1 (en) * | 2018-10-22 | 2020-04-23 | Celex Oncology Innovations Limited | Gene therapy targeting the neonatal form of nav1.5 for treating cancer |
| AU2020370748B2 (en) * | 2019-10-24 | 2025-08-21 | Celex Oncology Innovations Limited | Combination treatments for cancer |
| US20230062361A1 (en) | 2020-01-21 | 2023-03-02 | Celex Oncology Innovations Limited | Monoclonal antibodies against neonatal nav1.5 |
| US20230139204A1 (en) | 2020-03-09 | 2023-05-04 | Celex Oncology Innovations Limited | Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells |
| EP4176880A4 (en) * | 2020-07-01 | 2024-07-03 | New Cancer Cure - Bio Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A 3-KETOACYL-COA THIOLASE INHIBITOR AND AN INHIBITOR OF CARNITINE ACYLCARNITINE TRANSPORTERS |
| AU2024357729A1 (en) | 2023-10-12 | 2026-04-09 | Celex Oncology Innovations Limited | Treatment of metastatic or invasive brain cancer |
| WO2025252860A1 (en) | 2024-06-04 | 2025-12-11 | Celex Oncology Innovations Limited | Ranolazine enantiomer for use in cancer treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003088915A2 (en) * | 2002-04-18 | 2003-10-30 | University Of Virginia Patent Foundation | Novel sodium channel blockers |
| WO2004062604A2 (en) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| US8835473B2 (en) * | 2004-04-16 | 2014-09-16 | Rutgers, The State University Of New Jersey | Methods and compositions for treating cancer |
| ES2691411T3 (es) | 2006-03-27 | 2018-11-27 | Wex Medical Limited | Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia |
| CA2716321A1 (en) * | 2008-02-21 | 2009-08-27 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| WO2010033581A1 (en) * | 2008-09-16 | 2010-03-25 | University Of Washington | Molecular modulators of the wnt/beta-catenin pathway |
| BR112013009086A2 (pt) * | 2010-10-13 | 2016-07-26 | Mustafa Bilgin Ali Djamgoz | tratamento de câncer/inibição de metástase |
-
2010
- 2010-10-13 BR BR112013009086A patent/BR112013009086A2/pt not_active IP Right Cessation
- 2010-10-13 EP EP10776791.5A patent/EP2627321A1/en not_active Withdrawn
- 2010-10-13 CN CN202110087549.9A patent/CN112755029A/zh active Pending
- 2010-10-13 EP EP19211429.6A patent/EP3653206A1/en not_active Ceased
- 2010-10-13 CN CN2010800703488A patent/CN103370060A/zh active Pending
- 2010-10-13 EP EP25174138.5A patent/EP4640281A3/en active Pending
- 2010-10-13 CA CA2851694A patent/CA2851694C/en active Active
- 2010-10-13 SG SG2013026968A patent/SG189352A1/en unknown
- 2010-10-13 EP EP16020321.2A patent/EP3132791B1/en active Active
- 2010-10-13 KR KR1020137012365A patent/KR20140032346A/ko not_active Withdrawn
- 2010-10-13 RU RU2013121744/15A patent/RU2013121744A/ru not_active Application Discontinuation
- 2010-10-13 DK DK16020321.2T patent/DK3132791T3/da active
- 2010-10-13 US US13/879,146 patent/US20130203764A1/en not_active Abandoned
- 2010-10-13 AU AU2010362412A patent/AU2010362412A1/en not_active Abandoned
- 2010-10-13 JP JP2013533265A patent/JP2013539778A/ja active Pending
- 2010-10-13 WO PCT/GB2010/001908 patent/WO2012049440A1/en not_active Ceased
-
2013
- 2013-04-10 IL IL225689A patent/IL225689A0/en unknown
-
2015
- 2015-10-13 US US14/881,952 patent/US20160096812A1/en not_active Abandoned
-
2017
- 2017-04-06 AU AU2017202267A patent/AU2017202267B2/en active Active
-
2018
- 2018-06-07 US US16/002,555 patent/US20180346431A1/en not_active Abandoned
-
2019
- 2019-09-19 US US16/576,178 patent/US11634398B2/en active Active
-
2022
- 2022-12-19 US US18/068,263 patent/US12534444B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012049440A1 (en) | 2012-04-19 |
| US20160096812A1 (en) | 2016-04-07 |
| CA2851694C (en) | 2019-02-26 |
| AU2017202267A1 (en) | 2017-04-27 |
| US20200017457A1 (en) | 2020-01-16 |
| IL225689A0 (en) | 2013-06-27 |
| US20130203764A1 (en) | 2013-08-08 |
| EP3653206A1 (en) | 2020-05-20 |
| JP2013539778A (ja) | 2013-10-28 |
| EP2627321A1 (en) | 2013-08-21 |
| EP3132791B1 (en) | 2019-11-27 |
| EP3132791A1 (en) | 2017-02-22 |
| US11634398B2 (en) | 2023-04-25 |
| AU2010362412A1 (en) | 2013-05-30 |
| US20230202994A1 (en) | 2023-06-29 |
| EP4640281A3 (en) | 2026-01-07 |
| US12534444B2 (en) | 2026-01-27 |
| AU2017202267B2 (en) | 2019-01-24 |
| DK3132791T3 (da) | 2020-03-09 |
| CN112755029A (zh) | 2021-05-07 |
| RU2013121744A (ru) | 2014-11-20 |
| US20180346431A1 (en) | 2018-12-06 |
| CN103370060A (zh) | 2013-10-23 |
| EP4640281A2 (en) | 2025-10-29 |
| SG189352A1 (en) | 2013-05-31 |
| KR20140032346A (ko) | 2014-03-14 |
| CA2851694A1 (en) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013009086A2 (pt) | tratamento de câncer/inibição de metástase | |
| NZ755605A (en) | Compositions for modulating tau expression | |
| EA201291031A1 (ru) | Способ лечения ожирения с применением антиоксидантных модуляторов воспаления | |
| MX2019013723A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| EA201390756A1 (ru) | Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний | |
| MX374452B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| IN2012DN01961A (https=) | ||
| GEP20197049B (en) | Compositions and methods for treating surface wounds | |
| BRPI1007996B8 (pt) | Método para tratar formações subterrâneas | |
| BRPI0817961A2 (pt) | Método para tratar uma formação subterrânea, e, fluido de tratamento | |
| EA201690713A1 (ru) | Гетероциклические соединения и их применения | |
| PL3030589T3 (pl) | Zmodyfikowany elastomer dienowy, sposób jego syntezy i zawierająca go kompozycja kauczukowa | |
| EP3054954A4 (en) | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma | |
| ZA201600453B (en) | Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders | |
| HK1226063A1 (zh) | 选择性grp94抑制剂和其用途 | |
| WO2012149472A9 (en) | Methods, compositions, and kits for treating and preventing neurological conditions | |
| EP3083569A4 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| CL2016000326A1 (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
| BR112015025347A2 (pt) | 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer | |
| EA201691177A1 (ru) | Ингибиторы серин/треонинкиназ | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| UA114417C2 (uk) | Інгібітори iap | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| BR112015009061A2 (pt) | métodos para prevenção da erosão do solo e do escoamento de água de um solo e solo tratado contra a erosão. | |
| ZA201901367B (en) | Inhibition of olig2 activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. PAGAR RESTAURACAO. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |